Penetration of cefonicid into human lung tissue and lymph nodes. 1990

M Cazzola, and M Polverino, and E Guidetti, and G Santangelo, and G Paizis, and G Monaco, and G D'Amato, and G Girbino
Division of Occupational Pulmonary Disease and Respiratory Allergy, A. Cardarelli Hospital, Naples, Italy.

The present study was undertaken in order to investigate the penetration of cefonicid, a long-acting parenteral cephalosporin, with enhanced activity against most gram-positive and gram-negative pathogens, into human lung tissue and lymph nodes in patients undergoing open thoracotomy. Samples of lung tissue, lymph nodes and serum were obtained at various times after a single intramuscular dose of 1 g. The concentration of cefonicid was assayed by an agar diffusion method with Bacillus subtilis used as the test organism. The mean concentrations of cefonicid in serum at 2, 4, 8, 12 and 24 h after the injection were 91.5, 66.1, 35.7, 21.8 and 2.9 micrograms/ml, respectively. The mean levels of cefonicid into the hilar lymph nodes at the same times were 22.3, 18.7, 12.0, 6.9 and 1.5 micrograms/ml, respectively, while its concentrations in lung tissue were lower than those in lung lymph nodes up to the 12th hour (12.1, 14.6, 7.8, 5.4 and 1.9 micrograms/ml, respectively). Our results show that cefonicid was well distributed in interstitial fluid from which pulmonary lymph is formed and that its concentrations in lung tissue and lymph nodes were sufficient to inhibit most pathogens involved in respiratory tract infections. This finding was considered important, because it demonstrated that the high binding by plasma protein of cefonicid did not prevent it from entering lung tissue and fluids in useful quantities.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015790 Cefonicid A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections. Cefonicid Disodium Salt,Cefonicid Monosodium,Cefonicid Monosodium Salt,Monocid,SK&F-75073,SKF-75073-2,Sodium Cefonicid,Cefonicid, Sodium,SK&F 75073,SK&F75073,SKF 75073 2,SKF750732

Related Publications

M Cazzola, and M Polverino, and E Guidetti, and G Santangelo, and G Paizis, and G Monaco, and G D'Amato, and G Girbino
February 1991, Journal of chemotherapy (Florence, Italy),
M Cazzola, and M Polverino, and E Guidetti, and G Santangelo, and G Paizis, and G Monaco, and G D'Amato, and G Girbino
January 1989, International journal of clinical pharmacology research,
M Cazzola, and M Polverino, and E Guidetti, and G Santangelo, and G Paizis, and G Monaco, and G D'Amato, and G Girbino
January 1984, Reviews of infectious diseases,
M Cazzola, and M Polverino, and E Guidetti, and G Santangelo, and G Paizis, and G Monaco, and G D'Amato, and G Girbino
November 1996, The Journal of antimicrobial chemotherapy,
M Cazzola, and M Polverino, and E Guidetti, and G Santangelo, and G Paizis, and G Monaco, and G D'Amato, and G Girbino
June 1949, Experientia,
M Cazzola, and M Polverino, and E Guidetti, and G Santangelo, and G Paizis, and G Monaco, and G D'Amato, and G Girbino
January 1984, Reviews of infectious diseases,
M Cazzola, and M Polverino, and E Guidetti, and G Santangelo, and G Paizis, and G Monaco, and G D'Amato, and G Girbino
October 2012, Nature biotechnology,
M Cazzola, and M Polverino, and E Guidetti, and G Santangelo, and G Paizis, and G Monaco, and G D'Amato, and G Girbino
January 2005, Clinical pharmacokinetics,
M Cazzola, and M Polverino, and E Guidetti, and G Santangelo, and G Paizis, and G Monaco, and G D'Amato, and G Girbino
January 1992, Drugs under experimental and clinical research,
M Cazzola, and M Polverino, and E Guidetti, and G Santangelo, and G Paizis, and G Monaco, and G D'Amato, and G Girbino
September 1984, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!